Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

NCT07244705 is registered in ClinicalTrials.gov with Anbogen Therapeutics, Inc. as lead sponsor.

NCT NCT07244705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07244705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)
Lead sponsor
Anbogen Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 30, 2025
Completion date
July 31, 2028
Enrollment
66 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), colorectal cancer (diagnosis), colorectal cancer metastatic, immunotherapy